NASDAQ:EYENEyenovia Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyenovia Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.57 +0.02 (+0.56 %) (As of 08/6/2020 04:00 PM ET) Add Compare Share Today's Range$3.52Now: $3.57▼$3.5750-Day Range$2.61MA: $3.13▼$4.2452-Week Range$1.11Now: $3.57▼$5.06Volume1,520 shsAverage Volume241,675 shsMarket Capitalization$70.61 millionP/E RatioN/ADividend YieldN/ABeta2.41 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Eyenovia has a potential upside of 250.1% from its current price of $3.57.Amount of Analyst CoverageEyenovia has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesEyenovia has received 137 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEyenovia has received 160 “underperform” votes. (Add your “underperform” vote.)Community SentimentEyenovia has received 53.87% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote “Outperform” if you believe EYEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 23.50% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 6.45% of the stock of Eyenovia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to decrease in the coming year, from ($1.07) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEN Previous Symbol CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone917-289-1117Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book5.03Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-21,160,000.00 Net MarginsN/A Return on Equity-171.98% Return on Assets-141.31%Miscellaneous EmployeesN/A Outstanding Shares19,780,000Market Cap$70.61 million Next Earnings Date8/12/2020 (Confirmed) OptionableNot Optionable $3.57 +0.02 (+0.56 %) (As of 08/6/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EYEN News and Ratings via Email Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Eyenovia (NASDAQ:EYEN) Frequently Asked Questions How has Eyenovia's stock been impacted by COVID-19 (Coronavirus)? Eyenovia's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYEN stock has increased by 23.1% and is now trading at $3.57. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eyenovia? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyenovia. When is Eyenovia's next earnings date? Eyenovia is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Eyenovia. How can I listen to Eyenovia's earnings call? Eyenovia will be holding an earnings conference call on Wednesday, August 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Eyenovia's earnings last quarter? Eyenovia Inc (NASDAQ:EYEN) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01. View Eyenovia's earnings history. What price target have analysts set for EYEN? 4 Wall Street analysts have issued 1-year price targets for Eyenovia's shares. Their forecasts range from $6.00 to $19.00. On average, they expect Eyenovia's share price to reach $12.50 in the next year. This suggests a possible upside of 250.1% from the stock's current price. View analysts' price targets for Eyenovia. Has Eyenovia been receiving favorable news coverage? News stories about EYEN stock have trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyenovia earned a news impact score of -4.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Eyenovia. Are investors shorting Eyenovia? Eyenovia saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 96,700 shares, a decrease of 6.2% from the July 15th total of 103,100 shares. Based on an average trading volume of 114,200 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the shares of the stock are short sold. View Eyenovia's Current Options Chain. Who are some of Eyenovia's key competitors? Some companies that are related to Eyenovia include Trevena (TRVN), Menlo Therapeutics (MNLO), Magenta Therapeutics (MGTA), Osmotica Pharmaceuticals (OSMT), Immunic (IMUX), Ritter Pharmaceuticals (RTTR), REDHILL BIOPHAR/S (RDHL), Concert Pharmaceuticals (CNCE), NextCure (NXTC), Spero Therapeutics (SPRO), ProQR Therapeutics (PRQR), Urovant Sciences (UROV), Lannett (LCI), Northwest Biotherapeutics (NWBO) and Fortress Biotech (FBIO). View all competitors. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Axsome Therapeutics (AXSM), Opko Health (OPK), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), Energous (WATT), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Anavex Life Sciences (AVXL), Fate Therapeutics (FATE) and Nabriva Therapeutics (NBRV). Who are Eyenovia's key executives? Eyenovia's management team includes the following people: Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)Mr. Luke Clauson, VP of R&D (Age 40)Mr. John P. Gandolfo, CFO & Sec. (Age 58)Mr. Michael M. Rowe, VP of Marketing When did Eyenovia IPO? (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. What is Eyenovia's stock symbol? Eyenovia trades on the NASDAQ under the ticker symbol "EYEN." How do I buy shares of Eyenovia? Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eyenovia's stock price today? One share of EYEN stock can currently be purchased for approximately $3.57. How big of a company is Eyenovia? Eyenovia has a market capitalization of $70.61 million. The company earns $-21,160,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. What is Eyenovia's official website? The official website for Eyenovia is www.eyenoviabio.com. How can I contact Eyenovia? Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
